Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis

Clinical trial NCT05067127 · COMPLETED

Trial details

NCT number: NCT05067127
Sponsor: Apellis Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

C3G IC-MPGN C3 Glomerulopathy C3 Glomerulonephritis Complement 3 Glomerulopathy Complement 3 Glomerulopathy (C3G)Complement 3 Glomerulonephritis Dense Deposit Disease DDD Membranoproliferative Glomerulonephritis Membranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)

Start date: 2021-11-12
Primary completion: 2024-06-26
Enrollment: 124

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.